Early detection and significance of structural cardiovascular abnormalities in patients with Type 2 diabetes mellitus

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 1, 2008, Pages 109-125

  Somaratne, Jithendra B ^a   Whalley, Gillian A ^a   Bagg, Warwick ^a   Doughty, Robert N ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Coronary heart disease; Diabetes; Diabetic cardiomyopathy; Diastolic dysfunction; Left ventricular hypertrophy; Systolic dysfunction

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; DIAMICRON MR; ENALAPRIL; GLICLAZIDE; HYPERTENSIVE AGENT; LOSARTAN; NATRIURETIC FACTOR; UNCLASSIFIED DRUG; VALSARTAN;

ANGIOCARDIOGRAPHY; BLOOD PRESSURE REGULATION; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIASTOLIC DYSFUNCTION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; GLYCEMIC CONTROL; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; PROGNOSIS; QRS COMPLEX; QT INTERVAL; REVIEW; SCINTIGRAPHY; SCREENING TEST; SILENT MYOCARDIAL ISCHEMIA; SURVIVAL RATE; SYSTOLIC DYSFUNCTION;

EID: 38049098697     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.1.109     Document Type: Review

References (167)

1. Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature 414(6865), 782-787 (2001).
2. American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2002. Diabetes Care 26(3), 917-932 (2003).
3. Cowie CC, Rust KF, Byrd-Holt DD et al. Prevalence of diabetes and impaired fasting glucose in adults in the US population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 29(6), 1263-1268 (2006).
4. Harris MI, Flegal KM, Cowie CC et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 21(4), 518-524 (1998).
5. Stamler J, Vaccaro, O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16(2), 434-444 (1993).
6. Movahed M-R, Hashemzadeh M, Mazen Jamal M. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int. J. Candiol. 105(3), 315-318 (2005).
7. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr. Rev. 25(4), 543-567 (2004).
8. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart future in the adult-summary article a report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Writing Committee to update the 2001 Guidelines for the evaluation and management of heart failure). J. Am. Coll. Cardiol. 46(6), 1116-1143 (2005).
9. Ikeda T, Matsuda K, Itoh H et al. Plasma levels of brain and atrial xatriuretic peptides elevate in proportion to left ventricular end-systolic wall stress in patients with aortic stenosis. Am. Heart J. 133(3), 307-314 (1997).
10. Vanderheyden M, Göethals M, Verstreken S et al. Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. J. Am. Coll. Cardiol. 44(12), 2349-2354 (2004).
11. Iwanaga Y, Nishi I, Furuichi S et al. B-Type Natriuretic Peptide Strongly Reflects Diastolic Wall Stress in Patients With Chronic Heart Failure: Comparison Between Systolic and Diastolic Heart Failure. J. Am. Coll. Cardiol. 47(4), 742-748 (2006).
12. Rodelieffer RJ. Measuring plasma B-type natriuretic peptide in heart failure: Good to go in 2004? J. Am. Coll. Cardiol. 44(4), 740-749 (2004).
13. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal probrain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin. l Endocrinol. 47(3), 287-296 (1997).
14. Yano Y, Katsuki A, Gabizza EC et al. Plasma brain natriuretic peptide levels in normotensive noninsulin-dependent diabetic patients with microalbuminuria. J. Clin. Endocrinol. Metab. 84(7), 2353-2356 (1999).
15. Wang TJ, Larson MG, Levy D et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 109(5), 594-600 (2004).
16. Das SR, Drazner MH, Dries DL et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 112(14), 2163-2168 (2005).
17. Taylor JA, Christenson RH, Rao K, Jorge M, Gottlieb SS. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am. Heart J. 152(6), 1071-1076 (2006).
18. Magnusson M, Melander O, Israelsson B, Grubb A, Groop I, Jovinge S. Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care 27(8), 1929-1935 (2004).
19. Bhalla MA, Chiang A. Epshteyn VA et al. Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J. Am. Coll. Cardiol. 44(5), 1047-1052 (2004).
20. Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 48(1), 156-163 (2005).
21. Tarnow L, Hildebrandt P, Hansen BV, Borch-Johnsen K, Parving HH. Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy. Diabetologia 48(1), 149-155 (2005).
22. James SK, Lindahl B, Timmer JR et al. Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy). Am. J. Cardiol. 97(2), 167-172 (2006).
23. 2-terminal pro B-type natriuretic peptide in patients with diabetes and stable coronary heart disease. Diabetes Care 29(6), 1411-1413 (2006).
24. Tarnow L, Gall MA, Hansen BV, Hovind P, Parving HH. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia 49(10), 2256-2262 (2006).
25. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 241(19), 2035-2038 (1979).
26. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 23(2), 105-111 (1974).
27. Folsom AR, Szklo M, Stevens J, Liao F, Smith R, Eckfeldt JH. A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 20(6), 935 (1997).
28. Psaty BM, Furberg CD, Kuller LH et al. Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults: the Cardiovascular Health Study. Arch. Intern. Med. 159(12), 1339-1347 (1999).
29. Adult Treatment Panel III. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 106(25), 3143- (2002).
30. Cohn PF, Fox KM, Daly C. Silent Myocardial Ischemia. Circulation 108(10), 1263-1277 (2003).
31. Froelicher VF, Thomas MM, Pillow C, Lancaster MC. Epidemiologic study of asymptomatic men screened by maximal treadmill testing for latent coronary artery disease. Am. J. Cardiol. 34(7), 770-776 (1974).
32. Fazzini PF, Prati PL, Rovelli F et al. Epidemiology of silent myocardial ischemia in asymptomatic middle-aged men (the ECCIS Project). Am. J. Cardiol. 72(18), 1383-1388 (1993).
33. Koistinen MJ. Prevalence of asymptomatic myocardial ischaemia in diabetic subjects. Br. Med. J. 301(6743), 92-94 (1990).
34. Milan Study on Atherosclerosis and Diabetes (MiSAD) Group. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Am. J. Cardiol. 79(2), 134-139 (1997).
35. Lubaszewski W, Kawecka-Jaszcz K, Czarnecka D, Rajzer M, Stochmal A. Silent myocardial ischaemia in patients with essential arterial hypertension and non-insulin dependent diabetes mellitus. J. Hum. Hypertens. 13(5), 309 (1999).
36. Janand-Delenne B, Savin B, Habib G, Bory M, Vague P, Lassmann-Vague V. Silent myocardial ischemia in patients with diabetes: who to screen. Diabetes Care 22(9), 1396-1400 (1999).
37. Bacci S, Villella M, Villella A et al. Screening for silent myocardial ischaemia in type 2 diabetic patients with additional atherogenic risk factors: applicability and accuracy of the exercise stress test. Eur. J. Endocrinol. 147(5), 649-654 (2002).
38. Gazzaruso C, Garzaniti A, Giordanetti S et al. Assessment of Asymptomatic coronary artery disease in apparently uncomplicated Type 2 Diabetic Patients: A role for lipoprotein(a) and apolipoprotein(a) polymorphism. Diabetes Care 25(8), 1418-1424 (2002).
39. Fornengo P, Bosio A, Epifani G, Pallisco O, Mancuso A, Pascale C. Prevalence of silent myocardial ischaemia in new-onset middle-aged type 2 diabetic patients without other cardiovascular risk factors. Diabet. Med. 23(7), 775-779 (2006).
40. Wackers FJT, Young LH, Inzucchi SE et al. Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic Subjects: The DIAD study. Diabetes Care 27(8), 1954-1961 (2004).
41. Lee DP, Fearon WF, Froelicher VF. Clinical utility of the exercise ECG in patients with diabetes and chest pain. Chest 119(5), 1576-1581 (2001).
42. Rana BS, Davies JI, Band MM, Pringle SD, Morris A, Struthers AD. B-type natriuretic peptide can detect silent myocardial ischaemia in asymptomatic type 2 diabetes. Heart 92(7), 916-920 (2006).
43. Rutter MK, Wahid ST, McComb JM, Marshall SM. Significance of silent ischemia and microalbuminuria in predicting coronary events in asymptomatic patients with type 2 diabetes. J. Am. Coll. Cardiol. 40(1), 56-61 (2002).
44. Faglia E, Favales F, Calia P et al. Cardiac Events in 735 Type 2 Diabetic Patients Who Underwent Screening for Unknown Asymptomatic Coronary Heart Disease: 5-year follow-up report from the Milan Study on Atherosclerosis and Diabetes (MiSAD). Diabetes Care 25(11), 2032-2036 (2002).
45. Faglia E, Manuela M, Antonella Q et al. Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: an open-label randomized pilot study. Am. Heart J. 149(2), e1-6 (2005).
46. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham study. Am. J. Cardiol. 34(1), 29-34 (1974).
47. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 30(6), 595-602 (1972).
48. Lang RM, Bierig M, Devereux RB et al. Recommendations for chamber quantification: a report from the American Society of Echocardiographys Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J. Am. Soc. Echocardiogr. 18(12), 1440-1463 (2005).
49. Galderisi M, Anderson KM, Wilson PWF, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham Heart Study). Am. J. Cardiol. 68(1), 85-89 (1991).
50. Lee M, Gardin JM, Lynch JC et al. Diabetes mellitus and echocardiographic left ventricular function in free-living elderly men and women: The Cardiovascular Health Study. Am Heart J 133(1), 36-43 (1997).
51. Devereux RB, Roman MJ, Paranicas M et al. Impact of diabetes on cardiac structure and function: The Strong Heart Study. Circulation 101(19), 2271-2276 (2000).
52. Bruno G, Giunti S, Bargero G, Ferrero S, Pagano G, Perin PC. Sex-differences in prevalence of electrocardiographic left ventricular hypertrophy in Type 2 diabetes: The Casale Monferrato Study. Diabet. Med. 21(8), 823-828 (2004).
53. Fang ZY, Schull-Meade R, Leano R, Mottram PM, Prins JB, Marwick TH. Screening for heart disease in diabetic subjects. Am. Heart J. 149(2), 349-354 (2005).
54. Sato A, Tarnow L, Nielsen FS, Knudsen E, Parving HH. Left ventricular hypertrophy in normoalbuminuric Type 2 diabetic patients not taking antihypertensive treatment. QJM 98(12), 879-884 (2005).
55. Dawson A, Morris AD, Struthers AD. The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus. Diabetologia 48(10), 1971-1979 (2005).
56. Palmieri V, Tracy RE Roman MJ et al. Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the Strong Heart Study. Diabetes Care 26(10), 2764-2769 (2003).
57. Blackburn H. Classification of the electrocardiogram for population studies: Minnesota code. J. Electrocardiol. 2(3), 305-310 (1969).
58. Lewis T. Observations upon ventricular, hypertrophy, with special reference to preponderance of one or another chamber. Heart 5, 367-403 (1914).
59. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am. Heart J. 37(2), 161-186 (1949).
60. Casale PN, Devereux RB, Kligfield P et al. Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J. Am. Coll. Cardiol. 6(3), 572-580 (1985).
61. Casale PN, Devereux RB, Alonso DR, Campo E, Kligfield P. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation 75(3), 565-572 (1987).
62. Norman JE Jr, Levy D, Campbell G, Bailey JJ. Improved detection of echocardiographic left ventricular hypertrophy using a new electrocardiographic algorithm. J. Am. Coll. Cardiol. 21(7), 1680-1686 (1993).
63. Gubner R, Ungerleider HE. Electrocardiographic criteria of left ventricular hypertrophy. Factors determining the evolution of the electrocardiographic pattern in hypertrophy and bundle branch block. Arch. Intern. Med. 72, 196-209 (1943).
64. Siegel RJ, Roberts WC. Electrocardiographic observations in severe aortic valve stenosis: Correlative necropsy study to clinical, hemodynamic, and ECG variables demonstrating relation of 12-lead QRS amplitude to peak systolic transaortic pressure gradient. Am. Heart J. 103(2), 210-221 (1982).
65. Molloy TJ, Okin PM, Devereux RB, Kligfield P. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J. Am. Coll. Cardiol. 20(5), 1180-1186 (1992).
66. Levy D, Labib SB, Anderson KM, Christiansen JC, Kannel WB, Castelli WP. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation 81(3), 815-820 (1990).
67. Romhilt DW, Estes EH. A point-score system for the ECG diagnosis of left ventricular hypertrophy. Am. Heart J. 75(6), 752-758 (1968).
68. Verdecchia P, Schillaci G, Borgioni C et al. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension. J. Am. Coll. Cardiol. 31(2), 383-390 (1998).
69. Rautaharju PM, LaCroix AZ, Savage DD et al. Electrocardiographic estimate of left ventricular mass versus radiographic cardiac size and the risk of cardiovascular disease mortality in the epidemiologic follow-up study of the First National Health and Nutrition Examination Survey. Am. J. Cardiol. 62(1), 59-66 (1988).
70. de Vries SO, Heesen WF, Beltman FW et al. Prediction of the left ventricular mass from the electrocardiogram in systemic hypertension. Am. J. Cardiol. 77(11), 974-978 (1996).
71. Wolf HK, Burggraf GW, Cuddy E et al. Prediction of left ventricular mass from the electrocardiogram. J. Electrocardiol. 24(2), 121-127 (1991).
72. Dahlöf B, Devereux R, de Faire U et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am. J. Hypertens. 10(7 Pt 1), 705-713 (1997).
73. Hsieh BP, Pham MX, Froelicher VF. Prognostic value of electrocardiographic criteria for left ventricular hypertrophy. Am. Heart J. 150(1), 161-167 (2005).
74. Romhilt DW, Bove KE, Norris RJ et al. A critical appraisal of the electrocardiographic criteria for the diagnosis of left ventricular hypertrophy. Circulation 40(2), 185-195 (1969).
75. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J. Am. Coll. Cardiol. 25(2), 417-423 (1995).
76. Malmqvist K, Kahan T, Eriksson S et al. Evaluation of various electrocardiographic criteria for left ventricular hypertrophy in patients with stable angina pectoris: influence of using modified limb electrodes. Clin. Physiol. 21(2), 196-207 (2001).
77. Wachtell K, Smith G, Gerdts E et al. Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Am. J. Cardiol. 85(4), 466-472 (2000).
78. Mayet J, Shahi M, McGrath K et al. Left Ventricular Hypertrophy and QT Dispersion in Hypertension. Hypertension 28(5), 791-796 (1996).
79. Oikarinen La, Nieminen MSa, Viitasalo Ma et al. Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. J. Hypertens. 19(10), 1883-1891 (2001).
80. Chapman N, Mayet J, Ozkor M, Lampe FC, Thom SAM, Poulter NR. QT intervals and QT dispersion as measures of left ventricular hypertrophy in an unselected hypertensive population. Am. J. Hypertens. 14(5), 455-462 (2001).
81. Salles GF, Cardoso CRL, Deccache W. Multivariate associates of QT interval parameters in diabetic patients with arterial hypertension: importance of left ventricular mass and geometric patterns. J. Hum. Hypertens. 17(8), 561 (2003).
82. Salles G, Leocadio S, Bloch K, Nogueira AR, Muxfeldt E. Combined QT interval and voltage criteria improve left ventricular hypertrophy detection in resistant hypertension. Hypertension 46(5), 1207-1212 (2005).
83. Abergel E, Tase M, Menard J, Chatellier G. Influence of obesity on the diagnostic value of electrocardiographic criteria for detecting left ventricular hypertrophy. Am. J. Cardiol. 77(9), 739-744 (1996).
84. Okin PM, Roman MJ, Devereux RB, Kligfield P. ECG identification of left ventricular hypertrophy: Relationship of test performance to body habitus. J. Electrocardiol. 29(Suppl. 1), 256-261 (1996).
85. Okin PM, Jern S, Devereux RB, Kjeldsen SE, Dahlöf B, Group FT. Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients: the losartan intervention for endpoint (LIFE) reduction in hypertension study. Hypertension 35(1 Pt 1), 13-18 (2000).
86. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 55(4), 613-618 (1977).
87. Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol. 57(6), 450-458 (1986).
88. Schiller NB, Shah PM, Crawford M et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J. Am. Soc. Echocardiogr. 2(5), 358-367 (1989).
89. Reichek N, Helak J, Plappert T, Sutton MS, Weber KT. Anatomic validation of left ventricular mass estimates from clinical two-dimensional echocardiography: initial results. Circulation 67(2), 348-352 (1983).
90. Byrd BF 3rd, Finkbeiner W, Bouchard A, Silverman NH, Schiller NB. Accuracy and reproducibility of clinically acquired two-dimensional echocardiographic mass measurements. Am. Heart J. 118(1), 133-137 (1989).
91. Gopal AS, Schnellbaecher MJ, Shen Z, Akinboboye OO, Sapin PM, King DL. Freehand three-dimensional echocardiography for measurement of left ventricular mass: in vivo anatomic validation using explanted human hearts. J. Am. Coll. Cardiol. 30(3), 802-810 (1997).
92. Myerson SG, Bellenger NG, Pennell DJ. Assessment of left ventricular mass by cardiovascular magnetic resonance. Hypertension 39(3), 750-755 (2002).
93. Alfakih K, Reid S, Hall A, Sivananthan MU. The assessment of left ventricular hypertrophy in hypertension. J. Hypertens. 24(7), 1223-1230 (2006).
94. Katz J, Milliken MC, Stray-Gundersen J et al. Estimation of human myocardial mass with MR imaging. Radiology 169(2), 495-498 (1988).
95. Nakamura M, Tanaka F, Yonezawa S, Satou K, Nagano M, Hiramori K. The limited value of plasma B-type natriuretic peptide fbr screening for left ventricular hypertrophy among hypertensive patients. Am. J. Hypertens. 16(12), 1025-1029 (2003).
96. Vasan RS, Benjamin EJ, Larson MG et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 288(10), 1252-1259 (2002).
97. Struthers AD, Morris AD. Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 359(9315), 1430-1432 (2002).
98. Dawson A, Davies JI, Morris AD, Struthers AD. B-type natriuretic Peptide is associated with both augmentation index and left ventricular mass in diabetic patients without heart failure. Am. J. Hypertens. 18(12 Pt 1), 1586-1591 (2005).
99. Andersen NH, Poulsen SH, Knudsen ST, Heickendorff L, Mogensen CE. NT-proBNP in normoalbuminuric patients with Type 2 diabetes mellitus. Diabet. Med. 22(2). 188-195 (2005).
100. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 322(22), 1561-1566 (1990).
101. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham heart study. J. Am. Coll. Cardiol. 25(4), 879-884 (1995).
102. Sundstrom J, Lind L, Arnlov J, Zethelius B, Andren B, Lithell HO. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation 103(19), 2346-2351 (2001).
103. Okin PM, Roman MJ, Lee ET, Galloway JM, Howard BV, Devereux RB. Combined echocardiographic left ventricular hypertrophy and electrocardiographic ST depression improve prediction of mortality in American Indians: the Strong Heart Study. Hypertension 43(4), 769-774 (2004).
104. Casale PN, Devereux RB, Milner M et al. Value of Echocardiographic Measurement of Left Ventricular Mass in Predicting Cardiovascular Morbid Events in Hypertensive Men. Ann. Intern. Med. 105(2), 173-178 (1986).
105. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann. Intern. Med. 114(5), 345-352 (1991).
106. Loon E, Mathew J, Pogue J et al. Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. Eur. J. Cardiovasc. Prev. Rehabil. 10(6), 420-428 (2003).
107. Behar S, Reicher-Reiss H, Abinader E et al. Long-term prognosis after acute myocardial infarction in patients with left ventricular hypertrophy on the electrocardiogram. SPRINT Study Group. Am. J. Cardiol. 69(12), 985-990 (1992).
108. Yotsukura M, Suzuki J, Yamaguchi T et al. Prognosis following acute myocardial infarction in patients with ECG evidence of left ventricular hypertrophy prior to infarction. J. Electrocardiol. 31(2), 91-99 (1998).
109. Goldenberg I, Matetzky S, Hod H, Behar S, Freimark D. Outcome of patients with electrocardiographic evidence of left ventricular hypertrophy following thrombolytic therapy for acute myocardial infarction. Am. J. Cardiol. 88(9), 1024-1026 (2001).
110. Quinones MA, Greenberg BH, Kopelen HA et al. Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction. J. Am. Coll. Cardiol. 35(5), 1237-1244 (2000).
111. Lopez-Gomez JM, Verde E, Perez-Garcia R. Blood pressure, left ventricular hypertrophy and long-term prognosis in hemodialysis patients. Kidney Int. 68(Suppl.), S92-S98 (1998).
112. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 102(4), 470-479 (2000).
113. Boner G, Cooper ME, McCarroll K et al. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Diabetologia 48 (10), 1980-1987 (2005).
114. Milani RV, Lavie CJ, Mehra MR, Ventura HO, Kurtz JD, Messerli FH. Left ventricular geometry and survival in patients with normal left ventricular eiection fraction. Am. J. Cardiol. 97(7), 959-963 (2006).
115. Verdecchia P, Schillaci G, Borgioni C et al. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J. Am. Coll. Cardiol. 25(4), 871-878 (1995).
116. Pierdomenico, SD, Lapenna D, Bucci A, Manente BM, Cuccurullo F, Mezzetti A. Prognostic value of left ventricular concentric remodeling in uncomplicated mild hypertension. Am. J. Hypertens. 17(11 Pt 1), 1035-1039 (2004).
117. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med. 115(1), 41-46 (2003).
118. Hinderliter A, Sherwood A, Gullette ECD et al. Reduction of left ventricular hypertrophy after exercise and weight loss in overweight patients with mild hypertension. Arch. Intern. Med. 162(12), 1333-1339 (2002).
119. Verdecchia P, Angeli F, Borgioni C et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am. J. Hypertens. 16(11 Pt 1), 895-899 (2003).
120. Devereux RB, Wachtell K, Gerdts E et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292(19), 2350-2356 (2004).
121. Okin PM, Devereux RB, Gerdts E et al. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Circulation 113(12), 1588-1596 (2006).
122. Havranek EP, Esler A, Estacio RO, Mehler PS, Schrier RW. Differential effects of antihypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial. Am. Heart J. 145(6), 993-998 (2003).
123. Poirier P, Bogaty P, Garnean C, Marois L, Dumesnil JG. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 24(1), 5-10 (2001).
124. Zabalgoitia M, Ismaeil ME Anderson L, Maklady FA. Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am. J. Cardiol. 87(3), 320-323 (2001).
125. Liu JE, Robbins DC, Palmieri V et al. Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: The Strong Heart Study. J. Am. Coll. Cardiol. 41 (11), 2022-2028 (2003).
126. Boyer JK, Thanigaraj S, Schechtman KB, Perez JE. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am. J. Cardiol. 93(7), 870-875 (2004).
127. Valle R, Bagolin E, Canali C et al. The BNP assay does not identify mild left ventricular diastolic dysfunction in asymptomatic diabetic patients. Eur. J. Echocardiogr. 7 (1), 40-44 (2006).
128. Nicolino, A, Longobardi G, Furgi G et al. Lefi ventricular diastolic filling in diabetes mellitus with and without hypertension. Am. J. Hypertens. 8(4 Pt 1), 382-389 (1995).
129. Nishimura RA, Abel MD, Hatle LK, Tajik AJ. Assessment of diastolic function of the heart: background and current applications of Doppler echocardiography. Part 11. Clinical studies. Mayo Clin. Proc. 64(2), 181-204 (1989).
130. Cohen GI, Pietrolungo JF, Thomas JD, Klein AL. A practical guide to assessment of ventricular diastolic function using doppler echocardiography. J. Am. Coll. Cardiol. 27(7), 1753-1760 (1996).
131. Nishimura RA, Tajik AJ. Evaluation of Diastolic Filling of Left Ventricle in Health and Disease: Doppler Echocardiography Is the Clinician's Rosetta Stone. J. Am. Coll. Cardiol. 30(1), 8-18 (1997).
132. Oh JK, Appleton CP, Hatle LK, Nishimura RA, Seward JB, Tajik AJ. The noninvasive assessment of left ventricular diastolic function with two-dimensional and Doppler echocardiography. J. Am. Soc. Echocardiogr. 10(3), 246-270 (1997).
133. Choong CY, Herrmann HC, Weyman AE, Fifer MA. Preload dependence of Doppler-derived indexes of left ventricular diastolic function in humans. J. Am. Coll. Cardiol. 10(4), 800-808 (1987).
134. Dumesnil JG, Gaudreault G, Honos GN, Kingma JG Jr. Use of Valsalva maneuver to unmask left ventricular diastolic function abnormalities by Doppler echocardiography in patients with coronary artery disease or systemic hypertension. Am. J. Cardiol. 68(5), 515-519 (1991).
135. Hurrell DG, Nishimura RA, Ilstrup DM, Appleton CP. Utility of Preload Alteration in Assessment of Left Ventricular Filling Pressure by Doppler Echocardiography: A Simultaneous Catheterization and Doppler Echocardiographic Study. J. Am. Coll Cardiol. 30(2), 459-467 (1997).
136. Whalley GA, Walsh HJ, Gamble GD, Doughty RN. Comparison of different methods for detection of diastolic filling abnormalities. J. Am. Soc. Echocardiogr. 18(7), 710-717 (2005).
137. Pozzoli M, Traversi E, Cioffi G, Stenner R, Sanarico M, Tavazzi L. Loading manipulations improve the prognostic value of Doppler evaluation of mitral flow in patients with chronic heart failure. Circulation 95(5), 1222-1230 (1997).
138. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma Brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 109(25), 3176-3181 (2004).
139. Lubien E, DeMaria A, Krishnaswamy P et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings, Circulation 105(5), 595-601 (2002).
140. Epshteyn V, Morrison K, Krishnaswamy P et al. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 26(7), 2081-2087 (2003).
141. Shimabukuro M, Higa N, Oshiro Y, Asahi T, Takasu N. Diagnostic utility of brain-natriuretic peptide for left ventricular diastolic dysfunction in asymptomatic type 2 diabetic patients. Diabetes Obes. Metab. 9(3), 323-329 (2007).
142. Whalley, GA, Gamble GD, Doughty RN. The prognostic significance of restrictive diastolic filling associated with heart failure: a meta-analysis. Int. J. Cardiol. 116(1), 70-77 (2007).
143. Whalley GA, Gamble GD, Doughty RN. Restrictive diastolic filling predicts death after acute myocardial infarction: systematic review and meta-analysis of prospective studies. Heart 92(11), 1588-1594 (2006).
144. Somaratne JB, Whalley GA, Gamble G, Doughty RN. Restrictive filling pattern is a powerful predictor of heart failure events post-acute myocardial infarction and in established heart failure: a literature-based meta-analysis. J. Card. Fail. (In press).
145. Wang M, Yip GW, Wang AY et al. Tissue Doppler imaging provides incremental prognostic value in patients with systemic hypertension and left ventricular hypertrophy. J. Hypertens. 23(1), 183-191 (2005).
146. Poirier P, Garneau C, Bogaty P et al. Impact of left ventricular diastolic dysfunction on maximal treadmill performance in normotensive subjects with well-controlled type 2 diabetes mellitus. Am. J. Cardiol. 85(4), 473-477 (2000).
147. Saraiva RM, Duarte DM, Duarte MPC et al. Tissue Doppler imaging identifies asymptomatic normotensive diabetics with diastolic dysfunction and reduced exercise tolerance. Echocardiography 22(7), 561-570 (2005).
148. Fang ZY, Sharman J, Prins JB, Marwick TH. Determinants of exercise capacity in patients with Type II diabetes. Diabetes Care 28(7), 1643-1648 (2005).
149. Janardhanan R, Daley WL, Naqvi TZ et al Rationale and design: The VALsartan In Diastolic Dysfunction (VALIDD) Trial: Evolving the management of diastolic dysfunction in hypertension. Am. Heart J. 152(2), 246-252 (2006).
150. Solomon SD, Janardhanan R, Verma A et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet, 369(9579), 2079-2087 (2007).
151. Beljic T, Miric M. Improved metabolic control does not reverse left ventricular filling abnormalities in newly diagnosed non-insulin-dependent diabetes patients. Acta Diabetol. 31(3), 147-150 (1994).
152. Gough SC, Smyllie J, Barker M, Berkin KE, Rice PJ, Grant PJ. Diastolic dysfunction is not related to changes in glycaemic control over 6 months in type 2 (non-insulin-dependent) diabetes mellitus. A cross-sectional study. Acta Diabetol. 32(2), 110-115 (1995).
153. Felicio JS, Ferreira SRG, Plavnik FL et al. Effect of blood glucose on left ventricular mass in patients with hypertension and Type 2 diabetes mellitus. Am. J. Hypertens. 13(11), 1149-1154 (2000).
154. ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease - preterax and diamicron MR controlled evaluation. Diabetologia 44(9), 1118-1120 (2001).
155. Zieman SJ, Kass DA. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs 64(5), 459-470 (2004).
156. Mustonen JN, Uusitupa MI, Laakso M et al. Left ventricular systolic function in middle-aged patients with diabetes mellitus. Am. J. Cardiol. 73(16), 1202-1208 (1994).
157. Vinereanu D, Nicolaides E, Tweddel AC et al. Subclinical left ventricular dysfunction in asymptomatic patients with Type II diabetes mellitus, related to serum lipids and glycated haemoglobin. Clin. Sci. 105(5), 591-599 (2003).
158. Fang ZY, Leano R, Marwick TH. Relationship between longitudinal and radial contractility in subclinical diabetic heart disease. Clin. Sci. 106(1), 53-60 (2004).
159. Andersen NH, Poulsen SH, Eiskjaer H, Poulsen PL, Mogensen CE. Decreased left ventricular longitudinal contraction in normotensive and normoal buminuric patients with Type II diabetes mellitus: a Doppler tissue tracking and strain rate echocardiography study. Clin. Sci. 105(1), 59-66 (2003).
160. Loimaala A, Groundstroem K, Majahalme S, Nenonen A, Vuori I. Impaired myocardial function in newly onset Type 2 diabetes associates with arterial stiffness. Eur. J. Echocardiogr. 7(5), 341-347 (2006).
161. Greenbaum RA, Ho SY, Gibson DG, Becker AE, Anderson RH. Left ventricular fibre architecture in man. Br. Heart J. 45(3), 248-263 (1981).
162. Boyle AJ, Kelly DJ, Zhang Y et al. Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. J. Mol. Cell Cardiol. 39(2), 213-221 (2005).
163. Das SR, Drazner MH, Yancy CW, Stevenson LW, Gersh BJ, Dries DL. Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial. Am. Heart J. 148(5), 883-888 (2004).
164. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 327(10), 685-691 (1992).
165. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet, 361(9372), 1843-1848 (2003).
166. Andersen NH, Poulsen SH, Poulsen PL et al. Effects of blood pressure lowering and metabolic control on systolic left ventricular function in Type II diabetes mellitus. Clin. Sci. (Colch.) 111(1), 53-59 (2006).
167. American Diabetes Association. Standards of Medical Care in Diabetes - 2007. Diabetes Care 30(Suppl. 1), S4-41 (2007).